Brief: Apogee Therapeutics to Present 16-Week Phase 2 Data on APG777 for Atopic Dermatitis at EADV 2025
11/09/2025 12:38
Sept 11 (Reuters) - Apogee Therapeutics Inc APGE.O: APOGEE THERAPEUTICS ANNOUNCES LATE-BREAKER PRESENTATION OF 16-WEEK DATA FROM PHASE 2 APEX TRIAL OF APG777 FOR MODERATE-TO-SEVERE ATOPIC DERMATITIS AT THE UPCOMING EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY (EADV) 2025 CONGRESS Source text: ID:nGNX8q4s0M Further company coverage: APGE.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Apogee Therapeutics
See all newsNASDAQ TRADE HALT CONTINUES REASON NOT AVAILABLE AT 03:58 AM
NASDAQ TRADE HALT TRADING HALTED; FOR INFORMATION REQUESTED BY NASDAQ AT 07:50 PM
Brief: Abbvie Seeks At Least $8 Billion In Debt To Fund Apogee Deal - Bloomberg News
Street View: Strength in AbbVie's immunology pipeline to support revenue growth
AbbVie trims 2026 profit view on Apogee deal, tops second-quarter estimates (updated)